Alison R O'Brien from Palm Beach Gardens, FL, age 81

Resumes

Freelance Documentary Producer

view source

Location:

3230 Commerce Pl, West Palm Beach, FL 33407

Industry:

Broadcast Media

Work:

Lincoln Square Productions Mar 2016 - May 2016
Freelance Producer
Itv Sep 1, 2013 - Mar 2015
Freelance Tv Producer
Nbc News Jul 2011 - Jul 2013
Producer
Jwalking Designs Jul 2011 - Jul 2013
Co-Founder and Chief Executive Officer
Cnbc Jan 2005 - Jul 2011
Documentary and Long Form Producer

Education:

Seton Hall University 2011 - 2012
Masters, Leadership, Communications Syracuse University 1990 - 1994
Bachelors, Broadcast Journalism

Skills:

Television
Video Production
Video
Customer Service
Storytelling
Strategic Planning
Writing
Documentaries
Broadcast
Photoshop
Teaching
Negotiation
Microsoft Excel
Microsoft Office
Field Production
Html
Microsoft Word
Powerpoint
Windows
C++
C
Java

Interests:

Health

Manager

view source

Location:

West Palm Beach, FL

Industry:

Non-Profit Organization Management

Work:

BBTS
Mgr

Client Partner

view source

Location:

West Palm Beach, FL

Industry:

Information Technology And Services

Work:

Epsilon Aug 2010 - Jul 2014
Business Development - Financial and Insurance Services
Merkle Aug 2010 - Jul 2014
Client Partner
Acxiom Sep 1989 - Sep 2008
Client Executive
Perseus 1982 - 1987
Customer Service

Skills:

Database Marketing
Crm
Customer Acquisition
Direct Marketing
Strategic Partnerships
Multi Channel Marketing
Analytics
Strategy
Lead Generation
Customer Relationship Management
B2B Marketing
Marketing Strategy
Digital Marketing
Email Marketing
Segmentation
Salesforce.com
Integrated Marketing
Marketing Automation

Professor And Chair, Department Of

view source

Industry:

Research

Work:

Uniformed Services University of the Health Sciences since 1996
Professor and Chair, Department of Microbiology and Immunology
Uniformed Services University since Jul 1978
Professor and Chair, Department of Microbiology and Immunology

Alison O'brien

view source

Location:

United States

Us Patents

Humanized Monoclonal Antibodies That Protect Against Shiga Toxin Induced Disease
view source
US Patent:

20070003560, Jan 4, 2007
Filed:

Jun 20, 2006
Appl. No.:

11/471369
Inventors:

Jeffrey Stinson - Davie FL, US
Hing Wong - Weston FL, US
Alison O'Brien - Bethesda MD, US
Clare Schmitt - Rockville MD, US
International Classification:

A61K 39/40
C07H 21/04
C12P 21/06
C12N 5/06
C07K 16/12
US Classification:

424164100, 435069100, 435320100, 435326000, 530388400, 536023530
Abstract:

The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment or prevention of Shiga toxin induced diseases. One aspect of the invention is the humanized monoclonal antibody which binds Shiga toxin where the constant regions are IgG1-kappa and the variable regions are murine in origin. Yet another aspect of the invention is expression vectors and host cells transformed with such vectors which express the humanized monoclonal antibodies of the present invention.

Humanized Monoclonal Antibodies That Protect Against Shiga Toxin Induced Disease
view source
US Patent:

20070160607, Jul 12, 2007
Filed:

Jun 20, 2006
Appl. No.:

11/471420
Inventors:

Jeffrey Stinson - Davie FL, US
Hing Wong - Weston FL, US
Alison O'Brien - Bethesda MD, US
Clare Schmitt - Rockville MD, US
International Classification:

A61K 39/395
C07H 21/04
C12P 21/06
C12N 5/06
C07K 16/18
US Classification:

424145100, 435069100, 435326000, 435320100, 530388250, 536023530
Abstract:

The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment or prevention of Shiga toxin induced diseases. One aspect of the invention is the humanized monoclonal antibody which binds Shiga toxin where the constant regions are IgG1-kappa and the variable regions are murine in origin. Yet another aspect of the invention is expression vectors and host cells transformed with such vectors which express the humanized monoclonal antibodies of the present invention.

Humanized Monoclonal Antibodies That Protect Against Shiga Toxin Induced Disease
view source
US Patent:

20100166753, Jul 1, 2010
Filed:

Dec 28, 2009
Appl. No.:

12/647845
Inventors:

Jeffrey R. Stinson - Davie FL, US
Hing Wong - Weston FL, US
Alison D. O'Brien - Bethesda MD, US
Clare K. Schmitt - Rockville MD, US
International Classification:

A61K 39/40
A61P 13/12
A61P 19/02
A61P 37/02
A61P 1/02
US Classification:

4241331
Abstract:

The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment or prevention of Shiga toxin induced diseases. One aspect of the invention is the humanized monoclonal antibody which binds Shiga toxin where the constant regions are IgG1-kappa and the variable regions are murine in origin. Yet another aspect of the invention is expression vectors and host cells transformed with such vectors which express the humanized monoclonal antibodies of the present invention.

Humanized Monoclonal Antibodies That Protect Against Shiga Toxin Induced Disease
view source
US Patent:

20100189715, Jul 29, 2010
Filed:

Aug 6, 2009
Appl. No.:

12/536940
Inventors:

Jeffrey R. Stinson - Davie FL, US
Hing Wong - Weston FL, US
Alison D. O'Brien - Bethesda MD, US
Clare K. Schmitt - Rockville MD, US
Assignee:

Henry M. Jackson Foundation for the Advancement of Military Medicine - Rockville MD
Sunol Molecular Corporation - Miramar FL
International Classification:

A61K 39/395
A61P 31/04
US Classification:

4241331
Abstract:

The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment or prevention of Shiga toxin induced diseases. One aspect of the invention is the humanized monoclonal antibody which binds Shiga toxin where the constant regions are IgG1-kappa and the variable regions are murine in origin. Yet another aspect of the invention is expression vectors and host cells transformed with such vectors which express the humanized monoclonal antibodies of the present invention.

Humanized Monoclonal Antibodies That Protect Against Shiga Toxin Induced Disease
view source
US Patent:

20140135481, May 15, 2014
Filed:

Sep 25, 2013
Appl. No.:

14/036835
Inventors:

- Bethesda MD, US
Hing Wong - Weston FL, US
Alison D. O'Brien - Bethesda MD, US
Clare K. Schmitt - Rockville MD, US
Assignee:

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. - Bethesda MD
International Classification:

C07K 16/12
US Classification:

5303873
Abstract:

The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment or prevention of Shiga toxin induced diseases. One aspect of the invention is the humanized monoclonal antibody which binds Shiga toxin where the constant regions are IgG1-kappa and the variable regions are murine in origin. Yet another aspect of the invention is expression vectors and host cells transformed with such vectors which express the humanized monoclonal antibodies of the present invention.